Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

890
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
890
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

734
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
734
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parkinson's disease: Individual placebo responses are predicted by baseline expression of a striato-limbic network.

Research square·2026
Same author

Cell- and state-specific plasticity of striatal glutamatergic synapses is critical to the expression of levodopa-induced dyskinesia.

Neuron·2026
Same author

Non-invasive identification of brain signatures of acute liver injury.

Theranostics·2026
Same author

Utility of [<sup>18</sup>F]PI-2620 as Universal Biomarker for the Amyloid/Tau/Neurodegeneration Classification of Alzheimer Disease: An Exploratory Study with Dual-Phase PET Imaging.

AJNR. American journal of neuroradiology·2026
Same author

Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Preoperative network activity predicts the response to subthalamic DBS for Parkinson's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same journal

Key Interventions in Friedreich's Ataxia and Their Impact on Patient Outcomes: A Systematic Review.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Reply to Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: Jan 1, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Dyskinesia matters.

M Angela Cenci1, Sara Riggare2, Rajesh Pahwa3

  • 1Basal Ganglia Pathophysiology Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden.

Movement Disorders : Official Journal of the Movement Disorder Society
|December 25, 2019
PubMed
Summary
This summary is machine-generated.

Levodopa-induced dyskinesia (LID) significantly impacts Parkinson's disease (PD) patients. Preventing and treating LID remains a critical, unmet need for improving quality of life in PD.

Keywords:
animal modelsbasal gangliadrug developmentpathophysiologytherapy complications

More Related Videos

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Na&#239;ve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.3K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K

Related Experiment Videos

Last Updated: Jan 1, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Na&#239;ve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.3K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K

Area of Science:

  • Neurology
  • Movement Disorders
  • Parkinson's Disease Research

Background:

  • Levodopa-induced dyskinesia (LID) is a common and disabling complication of Parkinson's disease (PD) treatment.
  • LID negatively affects patient quality of life, causing motor and non-motor fluctuations, disability, and increased fall risk.
  • While severe LID prevalence may be decreasing due to cautious levodopa use, effective prevention strategies are still lacking.

Purpose of the Study:

  • To highlight the significant challenges posed by levodopa-induced dyskinesia (LID) in Parkinson's disease (PD).
  • To emphasize the unmet need for effective LID prevention and treatment strategies.
  • To advocate for continued translational research to improve outcomes for PD patients experiencing LID.

Main Methods:

  • This abstract reviews the clinical impact and current management challenges of LID in PD.
  • It discusses the limitations of existing treatments, including deep brain stimulation.
  • The focus is on the need for ongoing research and development.

Main Results:

  • Levodopa-induced dyskinesia (LID) remains a major source of discomfort and disability for Parkinson's disease (PD) patients.
  • Current advanced therapies like deep brain stimulation are only suitable for a small subset of patients.
  • There is currently no established method to prevent the development of LID.

Conclusions:

  • Preventing and effectively managing levodopa-induced dyskinesia (LID) is crucial for enhancing the quality of life for Parkinson's disease (PD) patients.
  • Translational research is essential to develop novel strategies for LID prevention and treatment.
  • The ultimate goal is to enable Parkinson's patients to experience the benefits of levodopa therapy without the burden of dyskinesia.